The methanolic extract of the aerial parts of
Phlomisbovei was fractionated and purified by combination of chromatographic methods to obtain five known flavones glucosides, and two cinnamic acid derivatives. Chrysoériol 7-
O-(3’’-
p-coumaroyl)-β-glucoside
(1) (
18), and
p-coumaric acid methyl ester
(2) (
19), were identified as mixture of
E and
Z forms, beside terniflorin (apigenin-7-
O-(6’’-
E-p-coumaroyl) glucoside)
(3) (
20), apigenin-7-
O-(6’’-(5’’’methoxy-coumaryl) glucoside
(4) (
21), apigenin 7-
O-(3″-
p-coumaryl) glucoside
(5) (
22)
, hispidulin-7-
O-glucuronide
(6) (
23), and chlorogenic acid
(7) (
24) (
Figure 1).
Compound 1a, Chrysoeriol 7-O-(3’’-(E)-p-coumaroyl)-β-glucoside: yellow solid
1HNMR (400 MHz, C3D6O). Aglycon moiety: d 6.70 (1H, s, H-3), d 6.45 (1H, m, H-6), d 6.84 (1H, d, J = 6.84 Hz, H-8), d 7.55 (1H, m, H-2’), d 6.93 (1H, d, J = 8.8 Hz, H-5’), d 7.90 (1H, d, J = 7.85 Hz, H-6’), δ 3.94 (3H, S, OMe), Glucose moiety: δ 5.22 (1H,m, H-1’’), δ 5.18 (1H, m, H-3’’), δ 3.92-3.63 (1H, signal patterns unclear due to overlapping, H2’’, H4’’, H5’’, H6’’), coumaroyl moiety: d 6.39 (1H, d, J = 15.7 Hz, H-a), d 7.63 (1H, d, J = 15.7 Hz, H-β), d 7.71 (2H, d, J = 8.5 Hz, H-2’’’/6’’’), d 6.81 (1H, d, J = 8.5 Hz, H3’’’/5’’’),. 13C NMR (100 MHz, C3D6O) d 164.3 (C2), d 102.7 (C3), d 177.6 (C4), d 156.2 (C5), d 99.1 (C6), d 165.4 (C7), d 94.1 (C8), d 150.2 (C9), d 101.6 (C10), d 121.4 (C1’), d 119.9 (C2’), d 147.4 (C3’), d 160.6 (C4’), d 114.8 (C5’), d 127.7 (C6’), d 54.8 (OMe), d 99.5 (C1’’), d 71.1 (C2’’), d 76.6 (C3’’), d 67.5 (C4’’), d 76.3 (C5’’), d 60.3 (C6’’), d 113.9 (Ca), d 144.2 (Cβ), d 125.1 (C1’’’), d 129.2 (C2’’’/6’’’), d 114.9 (C3’’’/5’’’), d 159.2 (C4’’’), d 166.2 (COO). UV spectrum, bands II and I respectively (MeOH, λmax, nm): 269, 316.
Compound 1b, Chrysoeriol 7-O-(3’’-(Z)-p-coumaroyl)-β-glucoside: 1HNMR and 13CNMR (400 MHz, C3D6O): Glucose moiety: δ 5.18 (1H, m, H-3’’), coumaroyl moiety: d 5.83 (1H, d, J = 12.9 Hz, H-a), d 6.86 (1H, d, J = 12.9 Hz, H-β), d 7.50(2H, d, J = 8.5Hz, H-2’’’/6’’’), δ 6.74 (2H, d, J = 8.5 Hz, H3’’’/5’’’),. 13C NMR (100 MHz, C3D6O) d 76.9 (C3’’), d 115.2 (Ca), d 142.4 (Cβ), d 125.6 (C1’’), d 132.0 (C2’’’/6’’’), d 113.8 (C3’’’/5’’’), d 158.0 (C4’’’), d 165.4 (COO).
Figure1, compound
2a,
p-coumaric acid methyl ester (E) : amorphous solid
1HNMR (400 MHz, CD
3OD): d 7,36 (1H, d,
J = 9.0 Hz, H-2), d 6, 68 (2H, d,
J = 9.0 Hz, H-3/5), d 7,36 (1H, d,
J = 9.0 Hz, H-6), d 6,19 (1H, d,
J = 15.0 Hz, H-a), d 7,58 (1H, d,
J = 15.0 Hz, H-β), d 3,77 (3H, s, Me).
13C NMR (100 MHz, CD
3OD): d 124.9 (C1), d 131.3 (C2/6), d 118.3 (C3/ 5), d 166.0 (C4), d 112.8 (Ca), d 147.4 (Cβ), d 170.4 (COO), d 51.6 (Me).
Compound 2b, p-coumaric acid methyl ester (Z) : 1HNMR (400 MHz, C3D6O): d 7,6 (1H, d, J = 9.0 Hz, H-2/6), d 6,81 (1H, d, J = 9.0 Hz, H-3), d 5,67 (1H, d, J = 15 Hz, H-a), d 3,71(3H, s, Me). 13C NMR (100 MHz, CD3OD): d 126.6 (C1), d 133.9 (C2/6), d 116.7 (C3/5), d 162.8 (C4), d 114.9 (Ca), d 145.6 (Cβ), d 169.0 (COO), d 51.4 (Me).
Compound 3, Terniflorin (apigenin-7-O-(6’’-E-p-coumaroyl)glucoside: white powder, 1HNMR (400 MHz, DMSO-d6): Aglycon moiety: d 6.79 (1H, s, H-3), d 6.46 (1H, d, J = 2.0 Hz, H-6), d 6.79 (1H, d, J = 2.0 Hz, H-8), d 7.91 (2H, d, J = 8.7 Hz, H-2’/6’), d 6.90 (2H, d, J = 8.8 Hz, H-3’/5’), d 12.97 (1H, s, OH-5), Glucose moiety: δ 5.16 (1H, d, J = 7.0 Hz, H-1’’), δ 5.18 (1H, m, H-3’’), δ 4.16-3.25 (1H, signal patterns unclear due to overlapping, H2’’, H3’’, H4’’, H5’’, H6’’), coumaroyl moiety: d 6.31 (1H, d, J = 16.0 Hz, H-a),d 7.48 (1H, d, J = 16.0 Hz, H-β), d 7.35(2H, d, J = 8.5Hz, H-2’’’/6’’’), d 6.67 (2H, d, J = 8.5 Hz, H3’’’/5’’’). 13C NMR (100 MHz, DMSO-d6): d 162.9.6 (C2), d 102.8 (C3), d 182.2 (C4), d 161.3 (C5), d 99.4 (C6), d 164.4 (C7), d 94.7 (C8), d 150.8 (C9), d 105.4 (C10), d 120.7 (C1’), d 128.7 (C2’/6’), d 116 (C3’/5’), d 161.6 (C4’), d 99.4 (C1’’), d 73.0 (C2’’), d 76.1 (C3’’), d 69.9 (C4’’), d 74.0 (C5’’), d 63.6 (C6’’), d 113.8 (Ca), d 145.0 (Cβ), d 124.5 (C1’’’), d 130.2 (C2’’’/6’’’), d 115.7 (C3’’’/5’’’), d 160.0 (C4’’’), d 166.5 (CO). UV spectrum bands II and I respectively (MeOH, λmax, nm): 269, 320. Which was further confirmed by a positive HR-ESI-MS analysis (m/z 577[M-H]-).
Compound 4, Apigenin-7-O-(6’’-(5’’’methoxy-coumaroyl)) glucoside: white powder, 1HNMR (400 MHz, DMSO-d6): Aglycon moiety: d 6.68 (1H, s, H-3), d 6.49 (1H, d, J = 2.0 Hz, H-6), d 6.79 (1H, d, J = 2.0 Hz, H-8), d 7.89 (1H, d, J = 8.7 Hz, H-2’), d 6.96 (1H, d, J = 8.8 Hz, H-3’), d 6.84 (1H, d, J = 8.8 Hz, H-5’, d 7.49 (1H, d, J = 8.8 Hz, H-6’), Glucose moiety : d 5.16 (1H, d, J = 7.0 Hz, H-1’’), d 3.54 (1H, m, H-2’’), d 3.60 (1H, m, H-3’’), d 3.44 (1H, m, H-4’’), d 3.90 (1H, m J = 2.0, Hz, H-5’’), d 4.59-4.22 (2H, m, H-6’’), Coumaroyl: d 6.26 (1H, d, J = 16 Hz, H-a), d 7.47 (1H, d, J = 16 Hz, H-β), d 7.55 (1H, s, H-2’’’), d 7.52 (1H, s, H-6’’’), d 3.89 (3H, s, H-8), 13C NMR (100 MHz, CMSO-d6) : d 162.4 (C2), d 100.7 (C3), d 180.0 (C4), d 154.9 (C5), d 97.3 (C6), d 164.7 (C7), d 92.6 (C8), d 158.8 (C9), d 103.3 (C10), d 122.9 (C1’), d 126.1 (C2’), d 116.3 (C3’), d 163.2 (C4’), d 113.4 (C5’), d 127.7 (C6’), d 97.4 (C1’’), d 70.6 (C2’’), d 73.9 (C3’’), d 68.0 (C4’’), d 71.6 (C5’’), d 61.3 (C6’’), d 111.3 (Ca), d 143.0 (Cβ), d 124.2 (C1’’’), d 107.3 (C2’’’), d 145.7 (C3’’’), d 148.6 (C4’’’), d 107.3(C5’’’), d 118.2 (C6’’’), d180.0 (CO), d 53.3 (OMe). Which was further confirmed by a positive HR-ESI-MS analysis (m/z 607[M-H]-).
Compound 5, Apigenin-7-O-(3’’-p-coumaroyl) glucopyranoside: yellow powder. 1HNMR (400 MHz, CD3COCD3+D2O): Aglycon moiety: d 6.69 (1H, s, H-3), d 6.47 (1H, s, H-6), d 6.83 (1H, d, J = 7.8 Hz, H-8), d 7. 91 (2H, d, J = 7.8 Hz, H-2’/6’), d 6. 98 (2H, d, J = 7.5 Hz, H-3’/5’), Glucose moiety: d 5.28 (1H, d, J = 6.3 Hz, H-1’’), d 3.70 (1H, t, J = 8.0 Hz, H-2’’), d 5.18 (1H, t, J = 8.0 Hz, H-3’’), d 3.67 (1H, m, H-4’’), d 3.75 (1H, m, H-5’’), d 3.89-3.74 (2H, m, H-6’’), coumaroyl moiety: d 6.37 (1H, d, J = 15.8 Hz, H-a), d 7.62 (1H, d, J = 15.8 Hz, H-β), d 7.51 (2H, d, J = 8.0 Hz, H-2’’’/6’’’), d 6.83 (2H, d, J = 7.8 Hz, H-3’’’/5’’’), 13C NMR (100 MHz, CD3COCD3+D2O) : d 165.5 (C2), d 103.2 (C3), d 182.8 (C4), d 161.8 (C5), d 100.2 (C6), d 163.4 (C7), d 95.4 (C8), d 157.5 (C9), d 106.0 (C10), d 121.7 (C1’), d 128.9 (C2’/6’), d 116.3 (C3’/5’), d 163.4 (C4’), d 100.3 (C1’’), d 71.8 (C2’’), d 77.4 (C3’’), d 68.3 (C4’’), d 77.0 (C5’’), d 61.1 (C6’’), d 114.6 (Ca), d 145.6 (Cβ), d 126.0 (C1’’’), d 130.4 (C2’’’/6’’’), d 116.1 (C3’’’/5’’’), d 160.0 (C4’’’), d 167.6 (COO). UV spectrum bands II and I respectively (MeOH, λmax, nm): 270, 317. Which was further confirmed by a negative FAB-MS analysis (m/z 577 [M-H]-).
Compound 6, Hispidulin-7-O-glucuronide: yellow powder. 1HNMR (400 MHz, CD3OD): Aglycon moiety: d 6.65 (1H, s, H-3), d 6.97 (1H, s, H-8), d 7.88 (2H, d, J = 8.5 Hz, H-2’/6’), d 6.92 (1H, d, J = 8.8 Hz, H-3’/5’), d 3.89 (3H, s, OMe), Glucuronide moiety: d 5.20 (1H, d, J = 7.5 Hz, H-1’’’), d 3.61 (1H, m, H-2’’), d 3.59 (1H, m, H-3’’), d 3.62 (1H, m, H-4’’), d 4.03 (1H, d, J = 9.4 Hz, H-5’’), 13C NMR (100 MHz, CD3OD): d 166.9 (C2), d 103.7 (C3), d 184.4 (C4), d 154.1 (C5), d 134.3(C6), d 157.7 (C7), d 95.8 (C8), d 154.1 (C9), d 107.7 (C10), d 123.1 (C1’), d 129.7 (C2’/6’), d 117.0 (C3’/5’), d 162.9 (C4’), d 61.5 (OMe), d 101.8 (C1’’), d 74.5 (C2’’), d 77.5 (C2’’), d 77.5 (C3’’), d 73.1 (C4’’), d 76.6 (C5’’), d 174.0 (C6’’). Which was further confirmed by a negative ESI-MS analysis (m/z 475 [M-H]-).
Compound 7, Chlorogenic acid: 1HNMR (400 MHz, CD3OD): d 2.16-2.02 (2H, m, H-2), d 4.18 (1H, m, H-3), d 3.72 (1H, m, H-4), d 5.32 (1H, d, J = 3.8 Hz, H-5), d 2.20-2.06 (2H, m, H-6), d 7.03 (1H, d, J = 1.9 Hz, H-2’), d 6.77 (1H, d, J = 8.2 Hz, H-5’), d 6.94 (1H, d, J = 1.9 Hz, H-6’), d 7.55 (1H, d, J = 15.75 Hz, H-7’), d 6.29 (1H, d, J = 16.1 Hz, H-8’), 13C NMR (100 MHz, CD3OD): d 76.8 (C1), d 38.4 (C2), d 71.9 (C3), d 73.7 (C4), d 72.1 (C5), d 39.3 (C6), d 127.8 (C1’), d 115.2 (C2’), d 146.8 (C3’), d 149.6 (C4’), d 116.5 (C5’), d 123.0 (C6’), d 147.0 (C7’), d 115.3 (C8’), d 168.8 (C9’), d 173.8 (COO). Which was further confirmed by a negative ESI-MS analysis (m/z 353 [M+H]+).
The different extracts from
P. bovei were tested for the ability to scavenge DPPH and ABTS
+ free radicals and also for the capacity to reduce the cupric ion. The results are presented in
Table 1. The methanolic and hydromethanolic extracts showed the most significant antiradical activities towards the 1,1-diphenyl 2-picrylhydrazyl (DPPH) whereas the methanolic extract had a good antioxidant activity measured with the CUPRAC test with a TEAC = 0.23.
The other extracts exhibited a low antiradical activity since TEACs are less than 0.2 with DPPH, ABTS, or CUPRAC.
The activities of the phenolic compounds
1- 5 isolated from the MeOH extract were measured
via the DPPH, ABTS, and CUPRAC tests at different concentrations taking trolox as the positive drug (
Table 2).
The five compounds isolated showed no measurable radical scavenging activity toward DPPH.
The comparison between the antioxidant activity of compounds 3 and 5 shows that the TEAC measured with the CUPRAC test reveals large disparities. Compound 3 is almost 4 times more active than trolox (TEACCUPRAC = 3.68 vs. TEACCUPRAC = 1.00 for Trolox), while compound 5 has an insignificant activity (TEAC = 0.04). These results are consistent in a sense with those described by Apak et al. (17 2004), which attribute a strong effect to the presence of a strong conjugated structure as in the cinnamic acid derivatives (Ar-CH = CH-COO), which cannot then be attacked by the cupric ion. However, our results show that this can be nuanced depending on the position of the coumaryl group on sugar. The presence of Z/E isomers is favorable to reduce the antioxidant capacity measured with CUPRAC as shown with TEAC values of compound 1 or 2 (TEAC = 0.14 and TEAC = 0.03 respectively). It is the same for the substitution by a methoxy group in meta position of the para-coumaryl nucleus (compound 4).
The TEAC value of compounds 1 (TEAC = 0.13) and 4 (TEAC = 0.19) were more active than the reference (rutin) (TEAC = 0.11) concerning radical scavenging properties toward ABTS+.
Concerning the genotoxicity studies, compound
3 was evaluated as non-genotoxic at all tested concentrations (
Table 3). Whereas compounds
1 (at 10 µg/assay), and
4 (at 50 µg/assay) are shown to be marginally genotoxic at the indicated concentrations. Therefore, DNA is not considered as a target for these compounds.
On the other hand, we studied the protective effect of flavones
1, 3, and
4 on NF induced damage. Dose of 10 µg/assay of NF was chosen for the antigenotoxicity studies, since this dose was not toxic and induced a significant SOS response. It is the dose that gives the maximum of genotoxicity for NF. As shown in
Table 4, compounds
1 and
3 reduce the genotoxicity induced by NF moderately by 86.6% and 64.6%, respectively, at the highest dose of 50 μg/assay. Lastly, compound
4 was the one showing the strongest activity, since it remains close to 90% of genotoxicity inhibition at low dose (2 μg/assay).
Flavonoids
3 and
4 are shown to possess a considerable antimutagenic potency in our experiments. This result can be explained by the presence of a pyrone group (nucleus C), two hydroxyl groups on C-4/C-5 in the flavonoid structure, as reported previously by Krizkova
et al. (
25) and Edenharder
et al. (
26). On the contrary, compound
1 showed the lowest diminution of antimutagenic effect compared to compounds
3 and
4, this effect could probably be ascribed to the methylation of the 3’-hydroxyl function as hypothesized by Edenharder
et al. (
26).
Chemical structures of compounds 1–7 isolated from Phlomis bovei de Noé
| Extrait | ABTS
| CUPRAC
| DPPH
|
|---|
| IC50 | ARP | TEAC | E‰ | TEAC | IC50 | ARP | TEAC |
|---|
| DCM | 3,08 | 0.32 | 0.01 | 0.01 | 0.04 | >476 | - | - |
| H2O | 0.40 | 2.5 | 0.1 | 0.04 | 0.19 | 1.49 | 0.67 | 0.08 |
| MeOH | 0.23 | 4.34 | 0.17 | 0.03 | 0.14 | 0.26 | 3.85 | 0.46 |
| H2O+MeOH | 0.23 | 4.34 | 0.17 | 0.05 | 0.23 | 0.24 | 4.17 | 0.50 |
| ABTS
| CUPRAC
| DPPH
|
|---|
| IC50* | ARP | TEAC | E‰ (L/g/cm) | TEAC | IC50** | ARP | TEAC |
|---|
| Trolox | 0.16 | 6.1 | 1.0 | 0.22 | 1.00 | 0.42 | 2.4 | 1.0 |
| Rutine | 0.34 | 2.9 | 0.11 | 0.66 | 3.3 | | | |
| | | | | | | | |
| 1 | 0.29 | 3.4 | 0.13 | 0.03 | 0.14 | >0.5 | - | - |
| 2 | 0.99 | 1.0 | 0.04 | 0.007 | 0.03 | >0.5 | - | - |
| 3 | 0.79 | 1.3 | 0.08 | 0.79 | 3.68 | Oxydant ou Prooxydanta | - | - |
| 5 | 0.52 | 1.9 | 0.07 | 0.01 | 0.04 | >0.5 | - | - |
| 4 | 0.21 | 4.8 | 0.19 | 0.13 | 0.05 | >0.5 | | |
| Compounds | Doses (μg/assay) | β-gal (U) | AP (U) | R | IF |
|---|
| NC | | 3.00 ± 0.02 | 21.40 ± 0 | 0.14 | |
| NF | | 70.51 ± 0 | 15.32 ± 0 | 4.60 | 32.8 |
| 1 | 50102 | 2.81 ± 0.024.43 ± 0.011.77 ± 0.02 | 16.88 ± 0.0118.38 ± 0.0114.52 ± 0.04 | 0.160.240.12 | 1.11.70.8 |
| 3 | 50102 | 2.09 ± 02.28 ± 0.052.36 ± 0.03 | 15.55 ± 015.16 ± 0.0115.33 ± 0.01 | 0.130.150.15 | 1.01.11.1 |
| 4 | 50102 | 4.03 ± 0.033.10 ± 0.023.03 ± 0 | 14.83 ± 017.55 ± 0.0315.55 ± 0.04 | 0.270.170.19 | 1.91.21.4 |
| Composés | Doses (μg/essai) | β-gal (U) | AP (U) | IF | IP (%) |
|---|
| NC | | 3.40 ± 0.01 | 17.9 ± 0.05 | | |
| NF | | 15.35 ± 0.04 | 5.4 ± 0.06 | 14.95 | |
| 1 | 50102 | 9.10 ± 0.0110.53 ± 011.00 ± 0 | 16.71 ± 016.02 ± 016.50 ± 0.01 | 2.863.453.50 | 86.682.482.0 |
| 3 | 50102 | 20.31 ± 0.0219.44 ± 020.10 ± 0.02 | 17.9 ± 016.94 ± 016.58 ± 0.02 | 5.936.026.37 | 64.663.961.5 |
| 4 | 50102 | 4.70 ± 06.69 ± 08.45 ± 0 | 17.40 ± 0.0216.20 ± 0.0116.00 ± 0.01 | 1.422.172.77 | 96.991.587.2 |